Its restrictions include its small sample relatively, insufficient randomization, and insufficient a control group of unexposed children. The relatively young age of the children at this planned interim analysis can be an additional limitation, and we plan to obtain more detailed assessments of the children at the age of 6 years. Because the NEAD study is not a randomized trial, a potential concern is that the outcomes may be due to confounding factors related to baseline characteristics that may affect the child’s IQ. For example, antiepileptic-drug assignment was not randomized, and then the largest proportion of moms taking valproate had idiopathic generalized epilepsy. However, the association between maternal valproate make use of and poor cognitive outcomes in the children persisted in analyses adjusted for most baseline characteristics, including the propensity analyses.The findings apply to people with acute myeloid leukemia whose cancer tumor cells have normal-looking chromosomes and a gene mutation known as MLL-PTD. Typically, these AML patients responded poorly following treatment with old standard therapies, relapsing within a 12 months often. Of AML individuals with normal chromosomes who absence the mutation, however, four in 10 are cured. The brand new study shows that treating patients who’ve the mutation with an aggressive therapy such as for example an autologous stem cell transplant while they are in remission might significantly extend their disease-free survival. An autologous transplant uses stem cells extracted from the patient’s own blood.